Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. The BSA-based method of dose calculation was adopted without adequate investigation of its ...

Promise of New Vascular-Disrupting Agents Balanced With Cardiac Toxicity: Is It Time for Oncologists to Get to Know Their Cardiologists? Drugs are to the medical oncologist what the scalpel is to the ...

Enhertu is a targeted medication used to treat specific HER2-positive or HER2-low cancers. Dosage is determined by body weight and the specific condition being treated. The following table shows ...

After a gradual adjustment period, the Hyqvia dose is 300-600 mg/kg, every 3 to 4 weeks. The dose is adjusted individually based on body weight, medical history, symptom severity, and treatment ...